MannKind Corporation specializes in drug-device combinations designed to treat chronic conditions such as diabetes, pulmonary hypertension, and fluid overload. The company's commercial portfolio includes Afrezza, an inhaled human insulin, and the V-Go wearable insulin delivery device for continuous subcutaneous infusion. Through a collaboration with United Therapeutics, MannKind developed and manufactures Tyvaso DPI, an inhaled treatment for pulmonary arterial hypertension and interstitial lung disease. In late 2025, the company expanded its cardiometabolic offerings by acquiring scPharmaceuticals, adding Furoscix, a subcutaneous furosemide injection. MannKind operates its primary manufacturing facility in Connecticut and is advancing a clinical pipeline that includes dry-powder formulations for idiopathic pulmonary fibrosis and nontuberculous mycobacterial lung disease.
